<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00905983</url>
  </required_header>
  <id_info>
    <org_study_id>CPNM-ANC-07</org_study_id>
    <nct_id>NCT00905983</nct_id>
  </id_info>
  <brief_title>Biweekly Gemcitabine and Docetaxel as First Line Treatment for Advanced Disease in Elderly Non-Small Cell Lung Cancer (NSCLC) Patients</brief_title>
  <official_title>Phase II Study of Biweekly Gemcitabine and Docetaxel as First Line Treatment for Advanced Disease in Elderly Non Small Cell Lung Cancer (NSCLC) Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Arnau de Vilanova</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Arnau de Vilanova</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Lung cancer is one of the most common malignancies worldwide and the leading cause of
      cancer-related deaths in Western countries. Standard treatment for patients with good
      performance status (PS) stage IIIB/IV NSCLC currently includes a two-drug platinum-based
      chemotherapy regimen, but optimum treatment for elderly patients is less well-defined due to
      platinum related toxicities. Several drugs with novel mechanisms of action and significant
      activity in NSCLC have been developed; including docetaxel and gemcitabine that are also
      active in patients previously treated with cisplatin-based regimens and have a more favorable
      toxicity profile. The more favorable toxicity profile of docetaxel and gemcitabine supports
      its use as first-line chemotherapy, especially in patients with severe comorbidities as
      elderly patients. To improve the therapeutic index of this combination, the investigators
      performed a study with biweekly gemcitabine and docetaxel in elderly patients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2007</start_date>
  <completion_date type="Anticipated">September 2011</completion_date>
  <primary_completion_date type="Anticipated">September 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate = sum of complete and partial tumour responses divided by the number of included patients</measure>
    <time_frame>2 &amp; 4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>time from study entry to death from any cause</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>biweekly</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>time from first response (CR or PR) to tumor progression</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>time from study entry to observed tumor progression or death due to progression disease</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of quality of life</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <arm_group>
    <arm_group_label>Gemcitabine and Docetaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients received biweekly docetaxel 50 mg/m2 iv, Gemcitabine 2000 mg/m2 iv days 1 and 14.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine and Docetaxel</intervention_name>
    <description>Docetaxel 50 mg/m2, IV, and Gemcitabine 2000 mg/m2, IV, on day 1 and 14 of each 28 day cycle. Number of Cycles: 6</description>
    <arm_group_label>Gemcitabine and Docetaxel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of advanced NSCLC.

          -  Stage III with pleural effusion and stage IV.

          -  Patients are 70 years old.

          -  Patients with 1 &gt; ECOG PS =1.

          -  Patients must have at least one measurable lesion, no previously irradiated.

          -  Life expectancy of at least 12 weeks.

          -  Adequate organ function according to the following criteria:

               -  Bone marrow: ANC &gt;= 2.0x10(9)cells/L; Platelet count &gt;= 100x10(9)cells/L;
                  Leukocyte count &gt;= 4000x10(6)/L; Hemoglobin &gt;= 10 g/dL.

               -  Liver function: Bilirubin &lt;= 1.5 X ULN; Alkaline phosphatase &lt;= 5 x ULN;AST and
                  ALT &lt;= 1.5 x ULN.

               -  Renal function: serum creatinine &lt;= 2mg/dL.

        Exclusion Criteria:

          -  Prior systemic chemotherapy for advanced disease.

          -  Patients with symptomatic brain metastases.

          -  No measurable bone metastases or malignant pleural effusion as only measurable lesion.

          -  History of prior malignancies, except curatively treated in situ carcinoma of the
             cervix or other cancer curatively treated and with no evidence of disease for at least
             five years.

          -  History of hypersensitivity reaction to study drugs.

          -  Concurrent treatment with other experimental drugs.

          -  Current peripheral neuropathy NCI grade 2.

          -  Participation in clinical trials within 30 days of study entry.

          -  Major surgery, open biopsy or traumatic lesion 28 days before to study start.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oscar Juan, Doctor</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Arnau de Vilanova de Valencia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Alfredo Sánchez, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Provincial de Castellón</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Muñoz, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>H. Universitario Dr. Peset</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sonia Maciá, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital General de Elda</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vicente Giner, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Sagunto</affiliation>
  </overall_official>
  <overall_official>
    <last_name>José Gómez, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Fe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gaspar Esquerdo, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clínica de Benidorm</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antonio López, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital San Juan de Alicante</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco Aparisi, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Virgen de los Lirios</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Miguel A. Muñoz, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Instituto Valenciano de Oncología</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Silvia Catot, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Althaia, Xarxa Asistencial de Manresa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Virgen de los Lirios</name>
      <address>
        <city>Alcoy</city>
        <state>Alicante</state>
        <zip>3804</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínica de Benidorm</name>
      <address>
        <city>Benidorm</city>
        <state>Alicante</state>
        <zip>03501</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Elda</name>
      <address>
        <city>Elda</city>
        <state>Alicante</state>
        <zip>03600</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Althaia, Xarxa Asistencial de Manresa</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Provincial de Castellón</name>
      <address>
        <city>Castellón de la Plana</city>
        <state>Castellón</state>
        <zip>12002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Sagunto</name>
      <address>
        <city>Sagunto</city>
        <state>Valencia</state>
        <zip>46520</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital San Juan de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03550</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Peset</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>May 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2009</study_first_submitted>
  <study_first_submitted_qc>May 19, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2009</study_first_posted>
  <last_update_submitted>May 19, 2009</last_update_submitted>
  <last_update_submitted_qc>May 19, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 21, 2009</last_update_posted>
  <responsible_party>
    <name_title>Vicente Alberola Candel</name_title>
    <organization>ASOCIACIÓN TERAPEUTICA EN HEMATOLOGÍA Y ONCOLOGÍA MÉDICAS H. ARNAU DE VILANOVA</organization>
  </responsible_party>
  <keyword>Carcinoma, Non-Small-Cell</keyword>
  <keyword>Elderly patients</keyword>
  <keyword>Docetaxel</keyword>
  <keyword>Gemcitabine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

